Supplementary Files
Keywords
Drugs, Essential
Neurological Rehabilitation
Social Vulnerability
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the social vulnerability of patients admitted to a hospital rehabilitation unit and their access to medications through the Unified Health System (SUS) of the Federal District (DF). Methods: This was an observational, descriptive, cross-sectional study using retrospective data of 99 patients hospitalized between January and December 2022. Sociodemographic and clinical variables and the presence of prescribed medications in the essential medicine lists of the World Health Organization (WHO), National List of Essential Medicines (RENAME), and the Essential Medicines List of the Federal District (REME-DF) were analyzed. Results: Of the medications, 93 (76.2%) were included in the REME-DF, 71 (58.2%) in the RENAME, and 63 (51.6%) in the WHO list. Social vulnerability was observed in 63% of patients. Conclusion: The REME-DF covers the most essential medications for rehabilitation, aligned with the National Pharmaceutical Assistance Policy (PNAF). However, the organization of health services in the DF should be restructured to overcome the barriers faced by people with disabilities in accessing medications.
References
AUDULV Å, et al. Managing everyday life: Self-management strategies people use to live well with neurological conditions. Patient Education and Counseling, 2021; 104(2): 413–421.
BERTOLDI AD, et al. Fontes de acesso e utilização de medicamentos na zona rural de Pelotas, Rio Grande do Sul, em 2016: estudo transversal de base populacional. Epidemiol. Serv. Saude, 2021; 30(1).
BRASIL. Ministério da Saúde. Conselho Nacional de Saúde. Resolução n. 338, de 06 de maio de 2004. Aprova a Política Nacional de Assistência Farmacêutica. Diário Oficial da União, Brasília, DF, 20 maio 2004. Seção 1, p.52.
BRASIL. Ministério do Desenvolvimento Social e Combate à Fome. Secretaria Nacional de Assistência Social.
Política Nacional de Assistência Social – PNAS/2004; Norma Operacional Básica – NOB/Suas. Brasília, 2005. Disponível em: https://www.mds.gov.br/webarquivos/publicacao/assistencia_social/Normativas/PNAS2004.pdf. Acessado em: 20 de dezembro de 2024.
BRASIL. Ministério da Saúde. Protocolos Clínicos e Diretrizes Terapêuticas - PCDT. Ministério da Saúde, 2021. Ministério da Saúde, 2021. Disponível em: https://www.gov.br/saude/pt-br/assuntos/pcdt. Acessado em: 29 de dezembro de 2024.
BRASIL. Ministério da Saúde. Relação Nacional de Medicamentos Essenciais (RENAME). Ministério da Saúde, 2022. Ministério da Saúde, 2022. Disponível em: https://www.gov.br/saude/pt-br/composicao/sectics/rename. Acessado em: 29 de dezembro de 2024.
CASTEL R. A dinâmica dos processos de marginalização: da vulnerabilidade à ``desfiliação’’. Ufba.br, 1997.
CLEMENTE KAP, et al. Barreiras ao acesso das pessoas com deficiência aos serviços de saúde: uma revisão de escopo. Revista de Saúde Pública, 2022; 56: 64.
CONRADIE T, et al. Rehabilitation and primary care treatment guidelines, South Africa. 2022.
DISTRITO FEDERAL. Secretaria de Estado de Saúde do Distrito Federal. Relação de Medicamentos do Distrito Federal (REME-DF). 2024a.
DISTRITO FEDERAL. Secretaria de Estado de Saúde do Distrito Federal. Protocolo - SES. Secretaria de Saúde do Distrito Federal. Secretaria de Saúde do Distrito Federal, 2024b. Disponível em: https://www.saude.df.gov.br/protocolo-ses. Acessado em: 29 de dezembro de 2024
DRAINONI ML, et al. Cross-Disability Experiences of Barriers to Health-Care Access. Journal of Disability Policy Studies, 2006; 17(2): 101–115.
EMLs around the world. Essentialmeds.org, [s.d.]. Disponível em: https://global.essentialmeds.org/dashboard/medicines. Acessado em: 29 de dezembro de 2024
EZZIANE Z. Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges. International Journal of Health Policy and Management, 2014; 3(7): 365–370.
FIORATI RC e ELUI VMC. Social determinants of health, inequality and social inclusion among people with disabilities. Rev. Lat. Am. Enfermagem, 2015; 23(2): 329–336.
LEVESQUE JF, et al. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int. J. Equity Health, 2013; 12: 18.
MAGARINOS-TORRES R, et al. Adesão às listas de medicamentos essenciais por médicos brasileiros em atuação no sistema único de saúde. Rev. Bras. Educ. Med., 2014; 38(3): 323–330.
MINELLI C, et al. Brazilian Academy of Neurology practice guidelines for stroke rehabilitation: part I. Arquivos de Neuro-Psiquiatria, 2022a; 80(6): 634–652.
MINELLI C, et al. Brazilian practice guidelines for stroke rehabilitation: Part II. Arquivos de Neuro-Psiquiatria, 2022b; 80(07): 741–758.
NAÇÕES UNIDAS BRASIL. Transformando nosso mundo: A Agenda 2030 para o desenvolvimento sustentável. 2015. Disponível em: https://brasil.un.org/pt-br/sdgs/3. Acessado em: 29 de dezembro de 2024.
NASCIMENTO RCRM, et al. Availability of essential medicines in primary health care of the Brazilian Unified Health System. Revista de Saúde Pública, 2017; 51: 10.
NORWEGIAN INSTITUTE OF PUBLIC HEALTH. WHO Collaborating Center for Drug Statistics Methodology. Index ATCDDD-ATC/DDD. Fhi.noNorwegian Institute of Public Health, 2024. Disponível em: https://atcddd.fhi.no/atc_ddd_index/. Acessado em: 29 de dezembro de 2024.
OLIVEIRA LCF, et al. O acesso a medicamentos em sistemas universais de saúde – perspectivas e desafios. Saúde em Debate, 2019; 43(spe5): 286–298.
PENCHANSKY R e THOMAS JW. The concept of access: definition and relationship to consumer satisfaction. Med. Care, 1981; 19(2): 127–140.
RANSMAYR G. Challenges of caregiving to neurological patients. Wiener Medizinische Wochenschrift, 2021; 171(11–12): 282–288.
ROCHA WH, et al. Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. Journal of Comparative Effectiveness Research, 2021; 10(6): 519–532.
ROVER MRM, et al. Acceso a medicamentos de alto precio en Brasil: la perspectiva de médicos, farmacéuticos y usuarios. Gaceta Sanitaria, 2016; 30(2): 110–116.
SCHULMAN-GREEN D, et al. Family Caregiver Support of Patient Self-Management During Chronic, Life-Limiting Illness: A Qualitative Metasynthesis. Journal of Family Nursing, 2021; 27(1): 55–72.
SMITH WT, et al. Disability in Cultural Competency Pharmacy Education. American Journal of Pharmaceutical Education, 2011; 75(2): 26.
TOMASIELLO DB, et al. TD 2832 - Desigualdades raciais e de renda no acesso à saúde nas cidades brasileiras. Texto para Discussão, 2023; 1–38.
VALENTIM RS, et al. Construção e validação de modelo lógico para Centros Especializados em Reabilitação. Revista de Saúde Pública, 2021; 55: 54.
VIEIRA FS. Assistência Farmacêutica no sistema público de saúde no Brasil. Rev Panam Salud Publica, 2010.
WALLACE LMK, et al. Social vulnerability as a predictor of mortality and disability: cross-country differences in the survey of health, aging, and retirement in Europe (SHARE). Aging Clin. Exp. Res., 2014; 27(3): 365–372.
WORLD HEALTH ORGANIZATION. Neurological disorders: public health challenges. World Health Organization, 2006.
WORLD HEALTH ORGANIZATION. Rehabilitation 2030: A call for action. Who.int, 7 fev. 2017. Disponível em: https://www.who.int/publications/m/item/rehabilitation-2030-a-call-for-action. Acessado em: 29 de dezembro de 2024.
WORLD HEALTH ORGANIZATION. Package of interventions for rehabilitation: module 3: neurological conditions. 2023.
WORLD HEALTH ORGANIZATION. Social determinants of health. Who.int, [s.d.]. Disponível em: https://www.who.int/health-topics/social-determinants-of-health#tab=tab_1. Acessado em: 29 de dezembro de 2024.